Full Text View
Tabular View
No Study Results Posted
Related Studies
Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial
This study is currently recruiting participants.
Study NCT00814255   Information provided by North Shore Long Island Jewish Health System
First Received: December 22, 2008   Last Updated: December 30, 2011   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2013
  Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Publications:
Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009 Jan;4(1):39-47. Epub 2008 Dec 10.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011 Feb 10;12(1):8.
Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan;55(1):50-60. Epub 2009 Nov 22.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services